Asclepii
Asclepii is a Cleveland-based medical device company that develops and sells FDA-cleared nanosilver hydrogel wound dressings (Poseidon) and is building a regenerative extracellular matrix platform (Artemis) for chronic and complex wounds.
- Company typePrivate
- Founded2022
- HeadquartersCleveland, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Asclepii firmographics
Firmographics- Name
- Asclepii
- Legal name
- Asclepii
- Website
- https://asclepii.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Asclepii is a Cleveland-based medical device company that develops and sells FDA-cleared nanosilver hydrogel wound dressings (Poseidon) and is building a regenerative extracellular matrix platform (Artemis) for chronic and complex wounds.
- Ownership category
- akta.pro rank
Asclepii industry classification
Industry- Product category
- Wound Care Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)
- akta.pro secondary industries
- Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Asclepii is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Asclepii business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Poseidon™ Product Sales: Direct sales of FDA-cleared nanosilver hydrogel wound dressings to consumers, clinics, and distributors. Products sold in 1 oz and 3 oz sizes, as individual units or cases of 12 units. Available in both OTC and Rx formulations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Poseidon™ Nanosilver Hydrogel 1 oz - Individual unit |
| Unit Pricing | Pay-as-you-go | Poseidon™ Nanosilver Hydrogel 3 oz - Individual unit |
| Unit Pricing | Pay-as-you-go | Case pricing - 12 units |
| Other | Pay-as-you-go | Payment plan option |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Asclepii product offering
Product offeringCore offering
Asclepii manufactures and sells the FDA-cleared Poseidon™ Nanosilver Hydrogel wound dressing in 1 oz and 3 oz formats, available OTC to consumers and by prescription to healthcare providers, using an ultra-low 10 ppm silver nanoparticle hydrogel that kills microbes and disrupts biofilms without contributing to antibiotic resistance. The company is also developing the Artemis Regenerative Wound Care Platform, an extracellular matrix scaffold technology for tissue regeneration in chronic and complex wounds such as diabetic foot ulcers and burns, which is being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.
Product overview
Asclepii offers a portfolio of wound care products centered around the Poseidon™ line of FDA-cleared nanosilver hydrogel wound dressings, available in 1 oz, 3 oz, and tube formats for both prescription (Rx) and over-the-counter (OTC) use. The Poseidon products feature ultra-low silver concentration (1 ppm) nanotechnology that kills microbes and disrupts biofilms without contributing to antibiotic resistance. In parallel, the company is developing the Artemis regenerative wound care platform—an extracellular matrix technology for tissue regeneration targeting chronic and complex wounds. The Poseidon line represents the company's current commercial products while Artemis represents its next-generation regenerative technology in development.
Differentiator
Problem solved
Functional benefit
Brands
- Poseidon™: FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management
- Artemis
Products and services
- Poseidon™ Nanosilver Hydrogel 1 oz FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management for consumers (OTC) and healthcare providers (Rx). Uses 10 ppm ultra-low silver nanoparticles to kill harmful microbes and disrupt biofilms without contributing to antibiotic resistance. Clinical observational data showed 96% of patients infection-free after 8 days.
- Poseidon™ Nanosilver Hydrogel 3 oz Larger 3 oz format of the FDA-cleared Poseidon Nanosilver Hydrogel wound dressing with the same ultra-low 10 ppm silver nanoparticle technology for topical wound management. Provides extended coverage for larger wounds and is sold OTC to consumers and by Rx to healthcare providers.
- Artemis Regenerative Wound Care Platform Extracellular matrix technology platform designed to support tissue regeneration and improve healing across chronic and complex wounds including diabetic foot ulcers and burns. Uses semi-synthetic cellular scaffolds that optimize cell adhesion, growth, and vascularization while reducing production costs by eliminating expensive bioreactor-based tissue engineering steps. Being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.
Quantifiable outcome
- 96% infection-free rate after 8 days - over 20% better than market leader (n=100)
- +2 more outcomes
Companies that use Asclepii
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Asclepii technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Asclepii partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Nottingham SpirkflagshipManufacturing and commercialization partnership to accelerate large-scale manufacturing and nationwide deployment of the Artemis regenerative wound care platform. Collaboration reflects shared commitment to strengthening U.S. biomanufacturing capabilities and addressing chronic wounds affecting approximately 6 million Americans annually. Nottingham Spirk brings expertise in product development and commercialization at scale.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Asclepii competitors and assessment
Company assessmentBroad incumbents
- Smith & Nephew: Global medical device leader with a large Advanced Wound Management portfolio (hydrogels, silver dressings, bioactives). Directly comparable to Asclepii in silver/antimicrobial wound dressings and adjacent regenerative products, but at vastly greater scale and with deep formulary penetration.
- ConvaTec: Specialist in advanced wound care, ostomy, and continence products, with a portfolio that includes silver-containing AQUACEL Ag dressings. Directly competes in the antimicrobial advanced wound dressing category Asclepii targets.
- Coloplast: Major wound care and ostomy player with Biatain Ag and similar silver-based dressings. Targets the same chronic wound (diabetic foot ulcer, pressure ulcer) end-markets and clinician segments as Asclepii.
- Mölnlycke Health Care: Swedish advanced wound care company (Mepilex Ag, Mepitel) and a global leader in antimicrobial and foam dressings. A direct head-to-head incumbent in the antimicrobial wound dressing category.
- 3M Health Care (Solventum): Owns the legacy KCI/Acelity negative pressure wound therapy franchise plus advanced wound dressings. Comparable to Asclepii as a broad incumbent in hospital-channel chronic wound care, though with a different primary modality.
Direct peers
- Organogenesis: Commercializes Apligraf and Dermagraft, the leading FDA-approved skin substitute / regenerative wound care products. Closest direct analog to Asclepii's Artemis platform, although priced at a premium tier.
- Integra LifeSciences: Develops regenerative tissue technologies (Integra Dermal Regeneration Template) and a broad wound care portfolio. Directly comparable to Asclepii's regenerative wound care ambition through Artemis.
- MiMedx: Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing. Comparable regenerative approach and end-market overlap with Asclepii's Artemis platform.
Emerging players
- MediWound: Israeli-listed biotech commercializing NexoBrid for burn wound debridement and developing a bioengineered skin substitute. Comparable to Asclepii in targeting chronic and burn wounds with a regenerative/biologic modality.
- PolarityTE: Regenerative medicine company developing autologous skin and soft tissue products (SkinTE). Comparable to Asclepii's Artemis as a smaller, emerging regenerative wound care player with similar early-stage commercialization challenges.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Asclepii social profiles
Digital presenceAsclepii compliance and trust
Trust signalCompliance2 records
Asclepii financial estimates
Financial estimateRevenue estimate
Valuation estimate
Asclepii leadership team
Management profileNumber of profiles
Profiles1 record
Asclepii funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Asclepii M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Asclepii
What does Asclepii do?
Asclepii manufactures and sells the FDA-cleared Poseidon™ Nanosilver Hydrogel wound dressing in 1 oz and 3 oz formats, available OTC to consumers and by prescription to healthcare providers, using an ultra-low 10 ppm silver nanoparticle hydrogel that kills microbes and disrupts biofilms without contributing to antibiotic resistance. The company is also developing the Artemis Regenerative Wound Care Platform, an extracellular matrix scaffold technology for tissue regeneration in chronic and complex wounds such as diabetic foot ulcers and burns, which is being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.
Is Asclepii a public or private company?
Asclepii is a private company. It is classified as venture growth investor backed and is currently operating.
When was Asclepii founded?
Asclepii was founded in 2022. It employs 11 to 50 people.
Where is Asclepii based?
Asclepii is headquartered in Cleveland, United States, in the North America region.
How does Asclepii make money?
One revenue line is on record: poseidon™ Product Sales.
Who are Asclepii's main competitors?
Broad incumbents on record are Smith & Nephew, ConvaTec, Coloplast, Mölnlycke Health Care and 3M Health Care (Solventum). Direct peers are Organogenesis, Integra LifeSciences and MiMedx. Emerging players are MediWound and PolarityTE.
Does Asclepii have an API?
No public API is recorded for Asclepii.
What industry is Asclepii in?
Asclepii's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAC, Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 3391 and its SIC code is 3841.